Trevi Therapeutics (TRVI) Accounts Payables (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Accounts Payables of $2.2 million for Q1 2026, up 55.88% year-over-year from $1.4 million in Q1 2025, and down 43.36% quarter-over-quarter from $3.9 million in Q4 2025.
Trevi Therapeutics (TRVI) Accounts Payables (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 55.88% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 55.88% YoY), while the FY2025 annual figure was $3.9 million, up 14.56% from the prior year.
- Accounts Payables for Q1 2026 stood at $2.2 million, down from $3.9 million in the prior quarter.
- The five-year high for Accounts Payables was $3.9 million in Q2 2022, with the low at $1.3 million in Q3 2023.
- The 5-year median for Accounts Payables is $2.1 million (2024), against an average of $2.3 million.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables jumped 116.98% in 2022, then tumbled 65.67% in 2023.
- Trevi Therapeutics' Accounts Payables stood at $2.9 million in 2022, then sank by 36.68% to $1.8 million in 2023, then soared by 88.72% to $3.4 million in 2024, then gained by 14.56% to $3.9 million in 2025, then tumbled by 43.36% to $2.2 million in 2026.
- Business Quant data shows TRVI's Accounts Payables at $2.2 million in Q1 2026, $3.9 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 3.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.10 Mn |
| Mar 31, 2026 | 2.22 Mn |
| Dec 31, 2025 | 3.91 Mn |
| Sep 30, 2025 | 2.71 Mn |
| Jun 30, 2025 | 2.97 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 3.41 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 1.81 Mn |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 2.86 Mn |
| Sep 30, 2022 | 2.33 Mn |
| Jun 30, 2022 | 3.94 Mn |
| Mar 31, 2022 | 1.74 Mn |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 2.23 Mn |